Yap Taz Signaling Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ, also known as WWTR1) are the principal transcriptional coactivators of the Hippo signaling pathway. Originally discovered as oncogenic proteins, YAP/TAZ have emerged as crucial regulators of neural stem cell proliferation, neuronal differentiation, brain development, and adult neurogenesis [1]. Recent research reveals that YAP/TAZ signaling is dysregulated in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS, where they influence neuronal survival, neuroinflammation, and regenerative responses [2].
flowchart TD
A[Hippo Pathway OFF] --> B[MST1/2 Kinases]
B --> C[LATS1/2 Kinases]
C --> D1[YAP Phosphorylation]
C --> D2[TAZ Phosphorylation]
D1 --> E1[14-3-3 Binding]
D2 --> E1
E1 --> F1[Cytoplasmic Retention]
E1 --> F2[Proteasomal Degradation]
A2[Hippo Pathway ON] --> B2[MST1/2 Inactive]
B2 --> C2[LATS1/2 Inactive]
C2 --> D3[YAP/TAZ Unphosphorylated]
D3 --> E2[Nuclear Translocation]
E2 --> F3[TEAD Transcription Factors]
F3 --> G1[Cell Proliferation Genes]
F3 --> G2[Anti-apoptotic Genes]
F3 --> G3[Stemness Genes]
F3 --> G4[CTGF, CYR61]
H[Aβ Pathology] --> I1[YAP/TAZ Inhibition]
H --> I2[Hippo Dysregulation]
I1 --> J1[Neuronal Death Susceptibility]
I1 --> J2[Reduced Neurogenesis]
K[α-Synuclein] --> L1[TAZ Sequestration]
L1 --> L2[Autophagy Impairment]
L2 --> L3[Protein Aggregation]
M[Neuroinflammation] --> N1[Cytokine Effects]
N1 --> N2[YAP/TAZ Nuclear Localization]
N2 --> N3[Pro-inflammatory Genes]
| Component |
Type |
Function in Neurodegeneration |
| YAP |
Transcriptional Coactivator |
Regulates gene expression, cell survival |
| TAZ/WWTR1 |
Transcriptional Coactivator |
YAP homolog, overlapping functions |
| MST1/2 |
Ser/Thr Kinases |
Hippo pathway kinases |
| LATS1/2 |
Ser/Thr Kinases |
Phosphorylate YAP/TAZ |
| TEAD1-4 |
Transcription Factor |
Primary DNA-binding partners |
| CTGF |
Target Gene |
Connective tissue growth factor |
| CYR61 |
Target Gene |
Cellular communication network factor |
| 14-3-3 |
Adapter Protein |
Binds phosphorylated YAP/TAZ |
| SAV1 |
Scaffold Protein |
Hippo pathway component |
YAP/TAZ signaling is significantly altered in AD [3]:
- Aβ-mediated inhibition: Aβ oligomers suppress YAP/TAZ nuclear localization through multiple mechanisms
- Hippo pathway dysregulation: Aβ activates MST1, increasing LATS1/2 activity and YAP/TAZ phosphorylation
- Neuronal vulnerability: YAP/TAZ promote neuronal survival; their inhibition increases vulnerability
- Neurogenesis impairment: Adult hippocampal neurogenesis requires YAP/TAZ; AD pathology suppresses this
- Tau pathology interaction: Tau can affect YAP/TAZ subcellular localization
YAP/TAZ play protective roles in PD models [4]:
- Dopaminergic neuron survival: YAP activation protects SNc neurons from degeneration
- α-Synuclein effects: α-Synuclein can sequester TAZ, impairing its function
- Autophagy regulation: TAZ promotes autophagy; loss contributes to protein aggregation
- Mitochondrial function: YAP/TAZ influence mitochondrial dynamics and quality control
- Therapeutic potential: YAP activators show promise in PD models
- Motor neuron protection: YAP activation provides protection to motor neurons
- TDP-43 pathology: YAP/TAZ can be sequestered by TDP-43 aggregates
- Astrocyte reactivity: YAP/TAZ in astrocytes modulate neuroinflammation
- Regenerative potential: Enhancing YAP/TAZ may promote neural repair
¶ Stroke and Brain Injury
- Ischemic damage: YAP/TAZ are activated in response to ischemia
- Neuroprotection: YAP activation can reduce infarct size
- Recovery: YAP/TAZ promote neural regeneration in recovery phases
| Agent |
Mechanism |
Status |
| YAP/TAZ agonists |
Promote nuclear localization |
Preclinical |
| Hippo inhibitors |
Block MST1/2 or LATS1/2 |
Research phase |
| TEAD modulators |
Enhance TEAD-YAP interaction |
Preclinical |
- YAP overexpression: AAV-mediated delivery in preclinical models
- TAZ delivery: Experimental approaches
| Approach |
Rationale |
Status |
| MST1 inhibitors |
Reactivate YAP/TAZ |
Preclinical |
| LATS1/2 inhibitors |
Prevent YAP/TAZ phosphorylation |
Research |
| Calcium channel modulation |
Affects Hippo signaling |
Research |
flowchart LR
subgraph Hippo
A[Hippo/YAP-TAZ Pathway]
end
subgraph Wnt
B[Wnt/β-catenin Pathway]
end
subgraph Notch
C[Notch Signaling]
end
subgraph PI3K
D[PI3K/Akt Pathway]
end
subgraph TGF
E[TGF-β Signaling]
end
A --> B
B --> A
A --> C
C --> A
A --> D
D --> A
A --> E
E --> A
- Wnt/β-catenin: YAP/TAZ and Wnt pathways cross-talk extensively in neural stem cells
- Notch signaling: Coordinate regulation of neurogenesis
- PI3K/Akt: Akt can phosphorylate YAP, providing integration point
- TGF-β: YAP/TAZ-Smad complexes in transcriptional regulation
| Biomarker |
Sample |
Relevance |
| YAP nuclear/cytoplasmic ratio |
Brain tissue |
Pathway activity |
| p-YAP (Ser127) |
Brain tissue |
Inhibition marker |
| CTGF levels |
CSF, brain tissue |
YAP/TAZ target |
| CYR61 levels |
CSF, brain tissue |
YAP/TAZ target |
The study of Yap Taz Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hippo-YAP/TAZ signaling in nervous system development
- YAP/TAZ in neurodegeneration: Emerging roles and therapeutic potential
- Hippo pathway in Alzheimer's disease: From pathogenesis to therapy
- YAP neuroprotection in Parkinson's disease models
- TAZ regulates autophagy in neurodegenerative diseases
- YAP/TAZ in adult neural stem cells and neurogenesis
- Hippo pathway in ALS: Role in motor neuron degeneration
- YAP-mediated neuroprotection after ischemic stroke
- YAP/TAZ-TEAD transcriptional co-activation in brain disease
- Cross-talk between Hippo and other pathways in neural development
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%